STOK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STOK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Stoke Therapeutics's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was $-2.380. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Dec. 2023.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.
As of today (2024-04-28), Stoke Therapeutics's current stock price is $ 12.41. Stoke Therapeutics's E10 for the fiscal year that ended in Dec. 2023 was $0.00. Stoke Therapeutics's Shiller PE Ratio of today is .
The historical data trend for Stoke Therapeutics's E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
E10 | Get a 7-Day Free Trial | - | - | - | - | - |
Stoke Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
E10 | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Stoke Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Shiller PE Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Stoke Therapeutics's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | -2.38 | / | 129.4194 | * | 129.4194 | |
= | -2.380 |
Current CPI (Dec. 2023) = 129.4194.
Stoke Therapeutics does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate it.
Stoke Therapeutics (NAS:STOK) E10 Explanation
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Be Aware
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
Thank you for viewing the detailed overview of Stoke Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
Barry Ticho | officer: Chief Medical Officer | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730 |
Ian F Smith | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Jonathan Allan | officer: General Counsel & Corp Sec | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730 |
Huw M. Nash | officer: COO & CBO | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730 |
Atp Life Science Ventures, L.p. | 10 percent owner | 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169 |
Atp Iii Gp, Ltd. | 10 percent owner | 230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169 |
Skorpios Trust | 10 percent owner | 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
Montrago Trustees Ltd | 10 percent owner | 195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
Blue Horizon Enterprise Ltd | 10 percent owner | 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
Ezbon International Ltd | 10 percent owner | 3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
Gene Liau | officer: EVP Research & Preclinical Dev | C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVE, BEDFORD MA 01730 |
Arthur A Levin | director | 1896 RUTHERFORD ROAD, CARLSBAD CA 92008 |
Stephen J Tulipano | officer: CFO | C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Arthur Tzianabos | director | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Kaye Edward M. Md | director, officer: CEO | 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011 |
From GuruFocus
By Business Wire Business Wire • 04-25-2023
By Business Wire • 01-04-2024
By Business Wire • 07-25-2023
By Business Wire Business Wire • 01-04-2023
By Business Wire Business Wire • 02-07-2023
By Business Wire Business Wire • 12-02-2022
By Business Wire Business Wire • 06-01-2022
By Business Wire • 01-17-2024
By Business Wire Business Wire • 08-25-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.